用于人體治療藥物的 ClinGuide CRISPR sgRNA
20 多年來(lái)，安捷倫為客戶提供開發(fā)、生產(chǎn)、過(guò)程檢測(cè)、原料分析、原料藥放行和穩(wěn)定性測(cè)試解決方案。安捷倫開發(fā)分析方法和 RNA 合成生產(chǎn)工藝，可針對(duì)您特定的向?qū)?RNA 優(yōu)化純度和產(chǎn)率。
- Oligonucleotide GMP Manufacturing
Request a Quote
Product Details
- 與階段相適應(yīng)的嚴(yán)格質(zhì)量體系包括 cGMP 標(biāo)準(zhǔn)和質(zhì)量源于設(shè)計(jì)方法
- 與質(zhì)譜兼容的高分辨率雜質(zhì)分析方法有助于確保您的 CRISPR 分子具有高純度
- 位于科羅拉多州的兩個(gè) cGMP 工廠可生產(chǎn)多種產(chǎn)品，并為多個(gè)項(xiàng)目提供支持，幫助您無(wú)縫轉(zhuǎn)入生產(chǎn)階段
- 由擁有 20 年以上經(jīng)驗(yàn)的科學(xué)家組成的專家團(tuán)隊(duì)，為多個(gè)臨床和商業(yè)項(xiàng)目的開發(fā)提供支持
- 與經(jīng)驗(yàn)豐富的伙伴合作，幫助您獲得長(zhǎng)期成功
- 項(xiàng)目經(jīng)理協(xié)調(diào)跨職能團(tuán)隊(duì)，以明確了解您的要求并確保項(xiàng)目成功完成
- Key Literature
-
Agilent ClinGuide CRISPR sgRNA for Human Therapeutics
Accelerate the clinical success of therapeutic gene editing programs.
- Flyers
- English
- 12 Oct 2023
- 1.12 MB
Accelerate Your Journey from Clinic to Market
Produce high-quality oligo APIs and efficiently advance from clinic to market, delivering therapeutics to patients with unmet medical needs
- Brochures
- English
- 28 Dec 2023
- 3.19 MB
Videos
Agilent to Acquire North American CDMO BIOVECTRA
Agilent Technologies signed a definitive agreement to acquire BIOVECTRA, a leading specialized contract development and manufacturing organization, for $925 million. Based in Canada, BIOVECTRA produces biologics, highly potent active pharmaceutical ingredients, and other molecules for targeted therapeutics. This expands Agilent’s end-to-end biopharma solutions that accelerate drug discovery, development, and manufacturing.
- Agilent to Acquire North American CDMO BIOVECTRA
- 22 Jul 2024
Agilent Investing $725 Million to Expand State-of-the-Art Manufacturing Capacity for Production of Nucleic Acid-Based Therapeutics
Investment will double capacity to produce active pharmaceutical ingredients used in therapeutics for a broad range of diseases. The addition of two new manufacturing lines (known as Trains C and D) will enable Agilent to meet growing demand for siRNA, antisense and CRISPR guide RNA molecules. Agilent expects customer shipments from the expansion to begin in 2026.
- 05 Dec 2022